Clinical Trials List
2022-02-01 - 2027-01-31
Phase II
Recruiting5
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳宜穎 Division of Hematology & Oncology
- 陳昱光 Division of Hematology & Oncology
- 賴學緯 Division of Hematology & Oncology
- 陳佳宏 Division of Hematology & Oncology
- 廖國秀 Division of General Surgery
- 張平穎 Division of Hematology & Oncology
- 黃子權 Division of Hematology & Oncology
- 陳宇欽 Division of Hematology & Oncology
- 葉人華 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林燕淑 Division of General Surgery
- Ling-Ming Tseng Division of General Surgery
- Yi-Fang Tsai Division of General Surgery
- 陳柏方 Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- Jiun-I Lai Division of Hematology & Oncology
- 邱仁輝 Division of General Surgery
- Chi-Cheng Huang Division of General Surgery
- 鄭涵方 Division of General Surgery
- 陳彥蓁 Division of General Surgery
- 賴亦貞 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
42 participants
-
Global
42 participants
